

Resource Summary Report

Generated by [dkNET](#) on Aug 29, 2026

LATS1/LATS2 Antibody

RRID:AB_2133375

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# A300-479A, RRID:AB_2133375

Antibody Information

URL: http://antibodyregistry.org/AB_2133375

Proper Citation: Thermo Fisher Scientific Cat# A300-479A, RRID:AB_2133375

Target Antigen: LATS1/LATS2

Host Organism: rabbit

Clonality: polyclonal

Comments: Discontinued; Applications: IP (2-10 µg/mg lysate), WB (1:1,000-1:5,000)

Antibody Name: LATS1/LATS2 Antibody

Description: This polyclonal targets LATS1/LATS2

Target Organism: mouse, human

Antibody ID: AB_2133375

Vendor: Thermo Fisher Scientific

Catalog Number: A300-479A

Record Creation Time: 20250819T232058+0000

Record Last Update: 20250820T050440+0000

Ratings and Alerts

No rating or validation information has been found for LATS1/LATS2 Antibody.

Warning: Discontinued: 2021

Discontinued; Applications: IP (2-10 µg/mg lysate), WB (1:1,000-1:5,000) **Warning:**

Discontinued at Thermo Fisher Scientific

Discontinued; Applications: IP (2-10 µg/mg lysate), WB (1:1,000-1:5,000)

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Cao X, et al. (2025) RIPK4 promotes epidermal differentiation through phase separation and activation of LATS1/2. Developmental cell.

Qi S, et al. (2023) Two Hippo signaling modules orchestrate liver size and tumorigenesis. The EMBO journal, e112126.

Ikeuchi M, et al. (2021) The tumor suppressor LATS2 reduces v-Src-induced membrane blebs in a kinase activity-independent manner. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(1), e21242.

Feng X, et al. (2019) A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Cancer cell, 35(3), 457.

Wu LMN, et al. (2018) Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. Cancer cell, 33(2), 292.

Moroishi T, et al. (2016) The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell, 167(6), 1525.